Search
Polymyxin B
go.drugbank.com/drugs/DB00781ApprovedInvestigationalVet approvedPolymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. … Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429].
Synonyms: Polymyxin B, Polimixina BInternational brands: Polomyxin BAvacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigationalAvacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. … It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA).
Albuterol
go.drugbank.com/drugs/DB01001ApprovedInvestigationalVet approvedSalbutamol is formulated as a racemic mixture of the R- and S-isomers. … The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity.
Mixtures: ULAX-C, UNIBRON RCategories: Adrenergic beta-2 Receptor Agonists, Cytochrome P-450 CYP3A InhibitorsLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.
Categories: CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesNADH
go.drugbank.com/drugs/DB00157ApprovedNutraceuticalIt forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed) … It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH).
Mixtures: Folika-V, Nutra-ZCategories: Heterocyclic Compounds, 2-RingArtemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.
Synonyms: β-artemether, β-dihydroartemisinin methyl etherMixtures: KOMEFAN ® 280, ARTEMETERO Y LUMEFANTRINAOxazepam
go.drugbank.com/drugs/DB00842ApprovedOxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … [A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions
Categories: Heterocyclic Compounds, 2-RingMigalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalapprove drugs for serious conditions where there is an unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients. … [L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate.
Synonyms: 1-Deoxygalactostatin, 1-DeoxygalactonojirimycinCategories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological Chaperones, Heterocyclic Compounds, 1-RingBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnBelantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
Categories: P-glycoprotein substratesRurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalFactor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous … Bleeding in joints is a common manifestation of hemophilia A, and bleeding episodes can be severe and life-threatening like intracranial hemorrhage.